130 related articles for article (PubMed ID: 38281442)
1. Survival outcome of patient with pT1N0 biliary tract cancer treated with surgery alone.
Kagoura M; Kobayashi S; Kojima M; Kudo M; Sugimoto M; Konishi M; Gotohda N
Eur J Surg Oncol; 2024 Mar; 50(3):107980. PubMed ID: 38281442
[TBL] [Abstract][Full Text] [Related]
2. A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).
Itano O; Takemura Y; Kishida N; Tamagawa E; Shinozaki H; Ikeda K; Urakami H; Ei S; Hayatsu S; Suzuki K; Sakuragawa T; Ishii M; Shito M; Aiura K; Fujisaki H; Takano K; Matsui J; Minagawa T; Shinoda M; Kitago M; Abe Y; Yagi H; Oshima G; Hori S; Kitagawa Y
BMC Cancer; 2020 Jul; 20(1):688. PubMed ID: 32703191
[TBL] [Abstract][Full Text] [Related]
3. A Multicenter Survey on Eligibility for a Randomized Phase III Trial of Adjuvant Chemotherapy for Resected Biliary Tract Cancer (JCOG1202, ASCOT).
Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
Ann Surg Oncol; 2023 Nov; 30(12):7331-7337. PubMed ID: 37450093
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant Chemotherapy and Outcomes in Older Adult Patients With Biliary Tract Cancer.
Gbolahan OB; Zhi X; Liu Y; Shah MM; Kooby DA; Alese OB
JAMA Netw Open; 2024 Jan; 7(1):e2351502. PubMed ID: 38206623
[TBL] [Abstract][Full Text] [Related]
5. Pitfalls, challenges, and updates in adjuvant systemic treatment for resected biliary tract cancer.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):547-554. PubMed ID: 33571059
[No Abstract] [Full Text] [Related]
6. Postoperative adjuvant chemotherapy for resectable cholangiocarcinoma.
Luvira V; Satitkarnmanee E; Pugkhem A; Kietpeerakool C; Lumbiganon P; Pattanittum P
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD012814. PubMed ID: 34515993
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of S-1 Adjuvant Chemotherapy for Resected Biliary Tract Cancer: A Retrospective Propensity-Matched Analysis.
Yoshida M; Yanagimoto H; Tsugawa D; Akita M; Urade T; Nanno Y; Fukushima K; Gon H; Komatsu S; Asari S; Kido M; Toyama H; Ajiki T; Fukumoto T
Am Surg; 2024 Jun; 90(6):1279-1289. PubMed ID: 38226586
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant systemic treatment in resected biliary tract cancer: State of the art, controversies, and future directions.
Rizzo A; Brandi G
Cancer Treat Res Commun; 2021; 27():100334. PubMed ID: 33592563
[TBL] [Abstract][Full Text] [Related]
9. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care.
Rizzo A; Brandi G
Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):483-485. PubMed ID: 33307876
[TBL] [Abstract][Full Text] [Related]
10. Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers.
Rhodin KE; Liu A; Bartholomew A; Kramer R; Parameswaran A; Uronis H; Strickler J; Hsu D; Morse MA; Shah KN; Herbert G; Zani S; Nussbaum DP; Allen PJ; Lidsky ME
Ann Surg Oncol; 2023 Aug; 30(8):4813-4821. PubMed ID: 37188803
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
Song S; Yang W; Tian H; Gong S; Lei C; Lv K; Lu T; Cheng Q; Yang K; Guo T
Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101788. PubMed ID: 34389530
[TBL] [Abstract][Full Text] [Related]
13. The role of surgery and adjuvant therapy in lymph node-positive cancers of the gallbladder and intrahepatic bile ducts.
Tran Cao HS; Zhang Q; Sada YH; Chai C; Curley SA; Massarweh NN
Cancer; 2018 Jan; 124(1):74-83. PubMed ID: 28841223
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection.
Li XH; Zhao CY; Zhou EL; Lin XJ
BMC Cancer; 2022 Nov; 22(1):1159. PubMed ID: 36357848
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study of patient-tailored FOLFIRINOX as a first-line chemotherapy for patients with advanced biliary tract cancer.
Ulusakarya A; Karaboué A; Ciacio O; Pittau G; Haydar M; Biondani P; Gumus Y; Chebib A; Almohamad W; Innominato PF
BMC Cancer; 2020 Jun; 20(1):515. PubMed ID: 32493242
[TBL] [Abstract][Full Text] [Related]
16. R0 but not R1/R2 resection is associated with better survival than palliative photodynamic therapy in biliary tract cancer.
Matull WR; Dhar DK; Ayaru L; Sandanayake NS; Chapman MH; Dias A; Bridgewater J; Webster GJ; Bong JJ; Davidson BR; Pereira SP
Liver Int; 2011 Jan; 31(1):99-107. PubMed ID: 20846273
[TBL] [Abstract][Full Text] [Related]
17. Lymphovascular and perineural invasion as selection criteria for adjuvant therapy in intrahepatic cholangiocarcinoma: a multi-institution analysis.
Fisher SB; Patel SH; Kooby DA; Weber S; Bloomston M; Cho C; Hatzaras I; Schmidt C; Winslow E; Staley CA; Maithel SK
HPB (Oxford); 2012 Aug; 14(8):514-22. PubMed ID: 22762399
[TBL] [Abstract][Full Text] [Related]
18. Oncological outcomes in patients with pT1N0-3 or pT2-3N0 gastric cancer after curative resection without adjuvant chemotherapy.
Yagi S; Nunobe S; Makuuchi R; Ida S; Kumagai K; Ohashi M; Sano T
Langenbecks Arch Surg; 2021 Mar; 406(2):419-426. PubMed ID: 33515064
[TBL] [Abstract][Full Text] [Related]
19. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
Edeline J; Hirano S; Bertaut A; Konishi M; Benabdelghani M; Uesaka K; Watelet J; Ohtsuka M; Hammel P; Kaneoka Y; Joly JP; Yamamoto M; Monard L; Ambo Y; Louvet C; Ando M; Malka D; Nagino M; Phelip JM; Ebata T
Eur J Cancer; 2022 Mar; 164():80-87. PubMed ID: 35182925
[TBL] [Abstract][Full Text] [Related]
20. DCK expression, a potential predictive biomarker in the adjuvant gemcitabine chemotherapy for biliary tract cancer after surgical resection: results from a phase II study.
Woo SM; Yoon KA; Hong EK; Park WS; Han SS; Park SJ; Joo J; Park EY; Lee JH; Kim YH; Kim TH; Lee WJ
Oncotarget; 2017 Oct; 8(46):81394-81404. PubMed ID: 29113399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
